Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases

Deregulation of cyclin-dependent kinases 4 and 6 (CDK4/6) is highly prevalent in cancer; yet, inhibitors against these kinases are currently used only in restricted tumour contexts. The extent to which cancers depend on CDK4/6 and the mechanisms that may undermine such dependency are poorly understood. Here, we report that signalling engaging the MET proto-oncogene receptor tyrosine kinase/focal adhesion kinase (FAK) axis leads to CDK4/6-independent CDK2 activation, involving as critical mechanistic events loss of the CDKI p21CIP1 and gain of its regulator, the ubiquitin ligase subunit SKP2. Combined inhibition of MET/FAK and CDK4/6 eliminates the proliferation capacity of cancer cells in culture, and enhances tumour growth inhibition in vivo. Activation of the MET/FAK axis is known to arise through cancer extrinsic and intrinsic cues. Our work predicts that such cues support cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases and identifies MET/FAK as a tractable route to broaden the utility of CDK4/6 inhibitor-based therapies in the clinic.

[1]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[2]  R. Finn,et al.  Treating cancer with selective CDK4/6 inhibitors , 2016, Nature Reviews Clinical Oncology.

[3]  Y. Choi,et al.  Signaling through cyclin D-dependent kinases , 2014, Oncogene.

[4]  C. Sherr.  The Pezcoller lecture: cancer cell cycles revisited. , 2000, Cancer research.

[5]  P. Workman,et al.  UKCCCR guidelines for the welfare of animals in experimental neoplasia. , 1988, British Journal of Cancer.

[6]  Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases , 2019, bioRxiv.

[7]  N. Dyson.  The regulation of E2F by pRB-family proteins. , 1998, Genes & development.

[8]  Agnieszka K. Witkiewicz,et al.  The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.

[9]  J. Guan,et al.  Regulation of the Cell Cycle by Focal Adhesion Kinase , 1998, The Journal of cell biology.

[10]  Anne-Marie Duchemin,et al.  Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. , 2007, Blood.

[11]  A. Newby,et al.  Focal Adhesion Kinase (FAK)-dependent Regulation of S-phase Kinase-associated Protein-2 (Skp-2) Stability , 2004, Journal of Biological Chemistry.

[12]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[13]  J. Biggs,et al.  Inhibitors of cyclin-dependent kinase and cancer , 1995, Journal of Molecular Medicine.

[14]  K. Pumiglia,et al.  Focal Adhesion Kinase Controls Cellular Levels of p27/Kip1 and p21/Cip1 through Skp2-Dependent and -Independent Mechanisms , 2006, Molecular and Cellular Biology.

[15]  B. Yalcin,et al.  A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer , 2017, Current medical research and opinion.

[16]  J. Dering,et al.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.

[17]  E. Winer,et al.  Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. , 2016, Cancer cell.

[18]  Anne E Carpenter,et al.  CellProfiler: image analysis software for identifying and quantifying cell phenotypes , 2006, Genome Biology.

[19]  J. Infante,et al.  Targeting CDK4/6 in patients with cancer. , 2016, Cancer treatment reviews.

[20]  Frederick A. Dick,et al.  Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit , 2007, Nature Cell Biology.

[21]  F. Puglisi,et al.  CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors , 2018, Front. Oncol..

[22]  K. Akashi,et al.  Mouse Development and Cell Proliferation in the Absence of D-Cyclins , 2004, Cell.

[23]  K. Hodivala-Dilke,et al.  Molecular Pathways: Endothelial Cell FAK—A Target for Cancer Treatment , 2016, Clinical Cancer Research.

[24]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[25]  UKCCCR guidelines for the welfare of animals in experimental neoplasia , 1988 .

[26]  Yu Shyr,et al.  Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives , 2012, BMC Genomics.

[27]  J. Brenton,et al.  Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. , 2007, Cancer cell.

[28]  R. Weinberg,et al.  An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. , 2013, Cancer cell.

[29]  Song Liu,et al.  The microarray gene profiling analysis of glioblastoma cancer cells reveals genes affected by FAK inhibitor Y15 and combination of Y15 and temozolomide. , 2014, Anti-cancer agents in medicinal chemistry.

[30]  Xiaobo Xia,et al.  Cell cycle-dependent regulation of a human DNA helicase that localizes in DNA damage foci. , 2004, Molecular biology of the cell.

[31]  Johannes Gerdes,et al.  The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.

[32]  D O Morgan,et al.  Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. , 1992, The EMBO journal.

[33]  V. Golubovskaya.  Targeting FAK in human cancer: from finding to first clinical trials. , 2014, Frontiers in bioscience.

[34]  Aleix Prat Aparicio.  Comprehensive molecular portraits of human breast tumours , 2012 .

[35]  Pierre Dubus,et al.  Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6 , 2004, Cell.

[36]  M. Pagano,et al.  Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer , 2008, Nature Reviews Cancer.

[37]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[38]  Toshikazu Nakamura,et al.  Hepatocyte growth factor and the Met system as a mediator of tumor–stromal interactions , 2006, International journal of cancer.

[39]  Julian Blagg,et al.  Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology , 2017, Cancer cell.

[40]  E. Knudsen,et al.  The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. , 2017, Trends in cancer.

[41]  S. Mittnacht,et al.  Mechanism-Based Screen Establishes Signalling Framework for DNA Damage-Associated G1 Checkpoint Response , 2012, PloS one.

[42]  G. Shapiro,et al.  Targeting CDK4 and CDK6: From Discovery to Therapy. , 2016, Cancer discovery.

[43]  P. Workman,et al.  Inhibitors of cyclin‐dependent kinases as cancer therapeutics , 2017, Pharmacology & therapeutics.

[44]  B. Engels,et al.  Targeting stroma to treat cancers. , 2012, Seminars in cancer biology.

[45]  Ai-Qin Jiang,et al.  FAK inhibitors in Cancer, a patent review , 2018, Expert opinion on therapeutic patents.

[46]  Rene H Medema,et al.  Rescue of Cyclin D1 Deficiency by Knockin Cyclin E , 1999, Cell.

[47]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[48]  Andrea Rocca,et al.  Progress with palbociclib in breast cancer: latest evidence and clinical considerations , 2017, Therapeutic advances in medical oncology.

[49]  M. Kitagawa,et al.  The consensus motif for phosphorylation by cyclin D1‐Cdk4 is different from that for phosphorylation by cyclin A/E‐Cdk2. , 1996, The EMBO journal.

[50]  L. Trusolino,et al.  The Met tyrosine kinase receptor in development and cancer , 2008, Cancer and Metastasis Reviews.

[51]  M. Blagosklonny,et al.  CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence , 2013, Cell cycle.

[52]  E. Knudsen,et al.  CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer , 2014, Oncotarget.

[53]  P. Kaldis,et al.  Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms , 2009, Oncogene.

[54]  P. Jackson,et al.  Putting transcription repression and protein destruction in pRb's pocket. , 2007, Developmental cell.

[55]  M. Dowsett,et al.  Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. , 2016, Cancer research.

[56]  E. Knudsen,et al.  Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure , 2010, Oncogene.

[57]  Daniele Repetto,et al.  Integrins and signal transduction. , 2010, Advances in experimental medicine and biology.